Motor neuron degeneration in spastic paraplegia 11 mimics amyotrophic lateral sclerosis lesions by Denora, Paola S. et al.
Motor neuron degeneration in spastic
paraplegia 11 mimics amyotrophic lateral
sclerosis lesions
Paola S. Denora,1,2,3,4,5, Katrien Smets,6,7,8, Federica Zolfanelli,9
Chantal Ceuterick-de Groote,10 Carlo Casali,11 Tine Deconinck,6,7 Anne Sieben,10,12
Michael Gonzales,13 Stephan Zuchner,13 Fre´de´ric Darios,2,3,4 Dirk Peeters,14
Alexis Brice,2,3,4,15 Alessandro Malandrini,16 Peter De Jonghe,6,7,8 Filippo M. Santorelli,17
Giovanni Stevanin,1,2,3,4,15 Jean-Jacques Martin10 and Khalid H. El Hachimi1,2,3,4
These authors contributed equally to this work.
The most common form of autosomal recessive hereditary spastic paraplegia is caused by mutations in the SPG11/KIAA1840 gene
on chromosome 15q. The nature of the vast majority of SPG11 mutations found to date suggests a loss-of-function mechanism of
the encoded protein, spatacsin. The SPG11 phenotype is, in most cases, characterized by a progressive spasticity with neuropathy,
cognitive impairment and a thin corpus callosum on brain MRI. Full neuropathological characterization has not been reported to
date despite the description of4100 SPG11 mutations. We describe here the clinical and pathological features observed in two
unrelated females, members of genetically ascertained SPG11 families originating from Belgium and Italy, respectively. We confirm
the presence of lesions of motor tracts in medulla oblongata and spinal cord associated with other lesions of the central ner-
vous system. Interestingly, we report for the first time pathological hallmarks of SPG11 in neurons that include intracytoplasmic
granular lysosome-like structures mainly in supratentorial areas, and others in subtentorial areas that are partially reminis-
cent of those observed in amyotrophic lateral sclerosis, such as ubiquitin and p62 aggregates, except that they are never labelled
with anti-TDP-43 or anti-cystatin C. The neuropathological overlap with amyotrophic lateral sclerosis, associated with some
shared clinical manifestations, opens up new fields of investigation in the physiopathological continuum of motor neuron
degeneration.
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Introduction
Hereditary spastic paraplegias (HSPs) are neurodegenera-
tive diseases, which include a large spectrum of inherited
disorders presenting with lower limb spasticity as the
common clinical feature (Harding, 1983). They are usually
classified according to their clinical presentation, pattern of
inheritance, age at onset and, more recently, their putative
physiopathological mechanism (Finsterer et al., 2012; Fink,
2013; Lo Giudice et al., 2014; Tesson et al., 2015).
Traditionally, and according to clinical criteria, which re-
mains the most operative for nosographic classification,
two forms of the disease are considered: the pure or un-
complicated forms, which represent the most frequent HSPs
in European countries, and the complex or complicated
forms, which are more frequent in recessively inherited
HSP and therefore in countries with a higher rate of con-
sanguinity (Boukhris et al., 2009; Ruano et al., 2014).
Besides the spasticity, the latter form is often characterized
by one or more additional neurological symptoms, such as
peripheral neuropathy, dementia or intellectual disability,
cerebellar ataxia, optic atrophy, deafness, retinopathy, etc.
(Harding, 1983). The variety of inheritance modes
(autosomal dominant, autosomal recessive, mitochondrial
and X-linked) and of mutated genes (470) contributes to
further heterogeneity of these neurodegenerative diseases
(Tesson et al., 2015).
One of the most common (14 to 26%) autosomal reces-
sive spastic paraplegias (AR-HSP) is caused by mutations in
the SPG11/KIAA1840 gene on chromosome 15q (SPG11;
MIM 610844) (Stevanin et al., 2007, 2008; Boukhris et al.,
2009; Crimella et al., 2009; Denora et al., 2009; Schu¨le et
al., 2009; Coutinho et al., 2013; Ishiura et al., 2014;
Pensato et al., 2014). This form is, in most cases, charac-
terized by a combination of progressive spasticity, cognitive
impairment, peripheral neuropathy and a thin corpus cal-
losum on brain MRI (Hehr et al., 2007; Stevanin et al.,
2008; Denora et al., 2009). Atypical cases of autosomal
recessive juvenile amyotrophic lateral sclerosis (ALS)
with long disease duration (Orlacchio et al., 2010; Daoud
et al., 2012) or with Charcot-Marie-Tooth disease
(Montecchiani et al., 2016) have also been found with mu-
tations in SPG11. The nature of the vast majority
of SPG11 mutations found to date suggests a mechanism
of loss-of-function of the encoded protein, spatacsin.
The function of spatacsin is indeed largely unknown
but its interaction with AP5Z1 (SPG48) (Slabicki et al.,
2010), a member of the adaptor-protein complex 5, sug-
gests that it plays a role in intracellular trafficking (Hirst et
al., 2013) and endolysosomal homeostasis in particular
(Hirst et al., 2015). An abnormal anterograde trafficking
has also been demonstrated in neurons derived
from induced pluripotent stem cells of SPG11 patients
(Pe´rez-Branguli et al., 2014). Recently, its requirement
for lysosome turnover and autophagy has also been evi-
denced (Chang et al., 2014; Renvoise´ et al., 2014; Varga
et al., 2015). Finally, the consequences of its knock-down
in zebrafish (Martin et al., 2012; Southgate et al.,
2010), together with the early age at onset in most pa-
tients, suggest a role for this gene during development of
the CNS.
Neuropathological reports of cases with spastic paraple-
gia are sparse and often without genetic–aetiological con-
siderations. We report here the clinical and pathological
description of two unrelated female autopsy cases, mem-
bers of genetically ascertained SPG11 families originating
from Belgium and Italy, respectively. We show that motor
neuron degeneration, particularly in spinal cord and me-
dulla oblongata, presents with histological lesions and
immunolabelling partially reminiscent of those observed
in ALS. This illustrates the overlap between HSPs and
ALS and should help to improve our understanding of
the physiopathological continuum of motor neuron degen-
eration. We also show that lysosomal-like granules accu-
mulate in agreement with the potential role of spatacsin.
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Materials and methods
Neuropathological studies
Full neuropathological examination was conducted according
to classical methods, including frozen and paraffin sections for
the Belgian case (Patient BG-2). Only paraffin sections from
frontal cortex, basal ganglia, cerebellum, medulla oblongata
and cervical spinal cord were available for the Italian case
(Patient IT). Brain sampling followed the ethical rules of
each country.
Frozen sections were stained for myelin (Spielmeyer), cy-
tology (Nissl), fibrillary glia (Holzer) and neutral fats (Sudan
III). Paraffin sections were stained for cytology (Nissl, haema-
toxylin and eosin, Masson’s trichrome), axons (Bodian silver
impregnation), myelin (Klu¨ver-Barrera) and carbohydrate
macromolecules (periodic acid-Schiff stain).
Stored formalin-fixed samples of the lumbar spinal cord as
well as deparaffinized spinal ganglia were further processed by
an additional 24 h fixation in 4% glutaraldehyde for conven-
tional electron microscopy. After post-fixation in 2% osmium
tetroxide, blocks were embedded in Araldite. Ultrathin sec-
tions were stained with uranyl acetate and lead citrate and
examined under an FEI CM10 Philips transmission electron
microscope.
Immunostaining was performed using the citrate buffer epi-
tope retrieval method. Endogenous peroxidase was quenched
by incubation for 20min at room temperature in a phosphate-
buffered saline (PBS)/0.1% TritonTM X-100 (Sigma) solution
containing 10% methanol and 0.003% H2O2. Microscope
slides carrying brain sections were washed three times and
incubated in the blocking solution (0.1% PBS, 4% TritonTM
X-100, 4% normal goat serum, 2% bovine serum albumin) for
1 h at room temperature. Sections were then incubated for 48 h
at 4 C with specific antibodies (Supplementary Table 1)
diluted in blocking solution against the following proteins:
cystatin C, ubiquitin, calbindin 28 kD, neurofilaments SMI31
and SMI32, hyperphosphorylated protein tau AT8, amyloid-
b17–24 4G8, TDP-43, GFAP, spatacsin, FUS, p62 and cathepsin
D. Sections were washed three times, incubated for 2 h at
room temperature with the corresponding biotinylated appro-
priate (anti-mouse or anti-rabbit) secondary antibody (1:250;
Vector Laboratories) diluted in blocking solution and washed
another three times. Bound antibodies were visualized using
the ABC amplification system (Vectastain ABC kit, Vector
Laboratories) with 3,3’-diaminobenzidine tetrahydrochloride
(DAB Metal Concentrate; Biogenex) as the substrate. The sec-
tions, nuclearly counterstained with haematoxylin or not, were
dehydrated twice in ethanol and xylene solutions and mounted
with Eukitt.
Neuronal loss, gliosis and atrophy were semiquantitatively
assessed and estimated as severe, moderate or absent by two
different observers.
Genetic analyses
Mutation screening of Patient IT (Italy) used an amplicon-
based Sanger sequencing method focused on the SPG11
gene, as previously reported (Stevanin et al., 2007).
DNA of the autopsy Patient BG-2 (Belgium) was not avail-
able but DNA from her affected sister Patient BG-3
(Supplementary Fig. 1) was subjected to whole exome sequen-
cing using the SureSelect 50Mb capture kit (Agilent) followed
by massive parallel sequencing in the Illumina HighSeq2000
sequencer. Sequence alignment to the human genome and vari-
ant annotation were performed as described elsewhere
(Gonzalez et al., 2014).
Results
Clinical outline of Italian and Belgian
patients
The Italian proband Patient IT (Supplementary Fig. 1) was
female, born by normal full-term delivery, after an unevent-
ful pregnancy. Her parents, of Italian ancestry, were
healthy and unrelated. Her initial growth and development
were normal. Onset of the disease manifested at the age of
10 years as a learning disability (Table 1). At 12 years of
age, she developed a mild motor disability, which pro-
gressed to a severe spastic-ataxic gait at age 18 years; walk-
ing was possible with one stick. At age 31 years she was
wheelchair-bound. Sagittal and axial T1-weighted and cor-
onal T2-weighted brain MRI (Supplementary Fig. 2A and
B), performed at age 14, showed corpus callosum thinning,
diffuse white matter abnormalities in frontal, occipital, tem-
poral and periventricular regions and atrophy of frontal
and occipital brain regions. MRI examination performed
at age 24 years (Supplementary Fig. 2C) confirmed the
severe evolution of the white matter and cortical abnorm-
alities. Neurological examination at 27 years, when she was
wheelchair-bound, showed lower and upper limb spasticity
with brisk reflexes as well as extrapyramidal rigidity, cere-
bellar ataxia in the four limbs, dementia and dysarthria,
and distal amyotrophy suggesting axonal peripheral neur-
opathy. No fasciculations were seen at that time.
Electroneuromyographic (ENMG) and nerve conduction
velocity recordings performed in the following years re-
vealed slightly reduced amplitudes of compound motor
action potentials, while amplitudes of sensory nerve
action potentials and motor and sensory nerve conduction
velocities (38 m/s in the tibial nerve, 48 m/s in the median
nerve) were normal. ENMG of the tibialis anterior muscle
showed chronic denervation with long durations and large
amplitudes of motor unit action potentials. The patient died
severely demented at 32 years of age of cardiopulmonary
arrest; a brain autopsy was performed 48 h after death.
Focused SPG11 gene analysis was performed by direct
sequencing in this patient.
Proband BG-2 was also female (Supplementary Fig. 1).
Her parents of Belgian origin were healthy and related.
Onset of the disease, at age 10 years, was characterized
by incoordination of all four limbs and intentional
tremor; subsequently, a stiff gait was noted. She had mild
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intellectual disability. She developed a spastic cerebellar
ataxic gait that progressed rapidly (Table 1). At age 20
years she was wheelchair-bound. She had sporadic general-
ized epileptic seizures. The EEG was normal at that time.
MRI of the brain was performed at age 36 years. T2-
weighted images showed diffuse white matter lesions in
periventricular areas and diffuse atrophy of the brain.
Neurological examination at age 36 years showed pyram-
idal signs with brisk reflexes in all four limbs and bilateral
Babinski sign, cerebellar ataxia, distal atrophy in all four
limbs and bilateral pes cavus. By age 45 years she had
complete quadriparesis, claw hands and bulbar palsy with
dysphagia and dysarthria. Severe feeding problems arose
due to the dysphagia and a percutaneous endoscopic gas-
trostomy tube was needed. No ENMG examination was
performed at this stage of the disease. She developed bra-
dypsychia and dementia. She died at the age of 46 years,
severely demented. Brain and spinal cord autopsy was per-
formed 24 h after death.
Patient BG-1, brother of proband Patient BG-2, is still
alive at age 53 years and also has mild intellectual disability
(Table 1). The disease started at 18 years of age. He de-
veloped an ataxic gait and later on, a stiffness in the lower
limbs. Distal amyotrophy was seen in all four limbs, with
claw hands. By age 29 years, he was wheelchair-bound due
to a severe spastic ataxic gait. No dementia and no bulbar
palsy were seen in this patient.
Patient BG-3, sister of proband Patient BG-2 is still alive
at age 51 years. She also has mild intellectual disability.
Onset of the disease was at age 10 years (Table 1). First,
she had a wide-based cerebellar ataxia. Later on a spastic
gait developed with distal amyotrophy in all limbs. She had
pes cavus. She became wheelchair-bound at the age of 20
years. She had dysarthric speech and saccadic eye move-
ments by age 24 years. The distal muscles became severely
atrophied and she developed complete bilateral drop-foot
and claw hands. Sporadic generalized epileptic seizures
were seen. Her EEG was normal. An ENMG examination
performed in the upper limbs at age 42 years showed
normal motor and sensory nerve conduction velocity re-
sponses (49 m/s and 53 m/s in the right ulnar and
median nerves) with normal amplitudes of the action po-
tentials. Signs of chronic neurogenic degeneration with
large motor units (polyphasic or giant motor unit poten-
tials) were seen in the thenar and hypothenar muscles and
in the first interosseous muscles. No clinical signs of bulbar
involvement were observed in this patient. Cognitive func-
tion remained normal. MRI of the brain performed at age
25 years showed a thin corpus callosum. Whole exome
sequence analysis was performed in this patient. Both
Belgian parents are deceased.
Genetic analyses
Whole exome sequencing in Patient BG-3 revealed the
homozygous truncating mutation c.6739_6742delGAGT
(p.Glu2247Leufs14) in exon 36 of SPG11. This mutation
was reported previously in other cases (Stevanin et al.,
2008) and was confirmed by Sanger sequencing
(Supplementary Fig. 1).
Direct Sanger sequencing of all exons of the SPG11 gene in
Patient IT revealed two unreported heterozygous truncating
mutations; c.2358_2359delinsTT (p.Glu786_Gly787delins
Aspfs) in exon 13 and c.4868delT (p.Leu1623Tyrfs17) in
exon 28. The two mutations were heterozygous in healthy
parents, the c.4868delT being found in the father and the
c.2358-2359delinsTT in the mother (Supplementary Fig. 1).
Macroscopic and myelinic modifica-
tions of brain autopsies
The autopsy of Patient IT was limited to brain and upper
cervical spinal cord. The brain was not weighed, but the
examination confirmed the data obtained by MRI, with
Table 1 Clinical characteristics of the SPG11 patients
Patient
/gender
Age at
motor
onset (y)
Age at
death
(y)
Disease
duration
(y)
Current
age
(y)
Intellectual
disability
(y)
Dementia
(y)
Spastic
ataxic gait
(y)
Epileptic
seizures
(y)
Bulbar
dysphagia
(y)
MRI
features
(Y)
Other
clinical
features
ITa,b/F 10 32 22 Deceased 10 27 12 Not
recorded
Not
recorded
Thin corpus callosum, peri-
ventricular white matter
abnormalities, fronto-
temporal and cerebellar
atrophy (14 and 24)
Distal amyotrophy, axonal
peripheral neuropathy,
cerebellar dysarthria
BG-2a/F 10 46 36 Deceased 10 545 10 20 45, PEG
tube
needed
Diffuse periventricular white
matter abnormalities,
cerebral atrophy (36)
Cerebellar dysarthria, pes
cavus, claw hands,
quadriparesis
BG-1/M 18 Alive 35 53 18 Not
recorded
18 Not
recorded
Not
recorded
Not available Distal amyotrophy, claw
hands
BG-3b/F 10 Alive 41 51 10 Not
recorded
10 42 Not
recorded
Thin corpus callosum (25) Cerebellar dysarthria, sac-
cadic eye movements,
pes cavus, distal amyot-
rophy, claw hands,
sporadic generalized
epileptic seizures
Patients BG-1, BG-2 and BG-3 belong to the same sibship. PEG = percutaneous endoscopic gastrostomy.
aAutopsy confirmed patients.
bDNA extraction.
F = female; M = male; y = years.
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atrophy of the cerebellum, particularly of the vermis. The
corpus callosum was also thin.
The autopsy of Patient BG-2 was also limited to the
brain, which weighed 950 g, and to the thoraco-lumbo-
sacral spinal cord. Macroscopic examination revealed
mild atrophy of the frontal lobe, severe thinning of the
corpus callosum, dilatation of the ventricular system and
a greyish aspect of the white matter, especially in subcor-
tical areas. There was some depigmentation of the substan-
tia nigra, a slight atrophy of the pons and atrophy of the
pyramids in the medulla oblongata as well as a thinning of
the spinal cord. There was no cerebellar atrophy but an
artificial discoloration of the inner granular cell layer; the
so-called e´tat glace´.
Myelin stains on frozen and paraffin sections in the
Belgian Patient BG-2 showed a myelin pallor of the white
matter in the cerebral hemispheres and a demyelination of
the corpus callosum (Supplementary Fig. 2E). There was
also demyelination of the pyramidal pathways in the me-
dulla oblongata and the spinal cord (crossed and uncrossed
tracts), of the dorsal and ventral spinocerebellar tracts and
also of the fasciculus gracilis. Myelin staining of spinal cord
of Patient IT (Klu¨ver-Barrera stain alone or associated with
Bodian silver impregnation) showed degeneration of
crossed and uncrossed pyramidal tracts. The atrophy
also involved the dorsal spinocerebellar tracts and the fas-
ciculus gracilis in the posterior columns (Supplementary
Fig. 2D).
CNS neuronal loss and astrogliosis
Cytological stains (haematoxylin and eosin, Masson’s tri-
chrome, cresyl violet) revealed neuronal loss in various re-
gions of the CNS in both patients (Table 2). In both cases,
the frontal cortex was severely altered, particularly the gyrus
cinguli, the frontal gyri, mainly in the third layer and, to a
lesser extent, the temporal gyri. Only a few, although shrun-
ken, Betz neurons remained in the precentral gyrus. In the
thalamus, focal neuronal loss was severe in the mediodorsal
nucleus and the lateral dorsal nucleus in both patients. The
caudate and putamen nuclei were only moderately affected
in Patient IT and were spared in Patient BG-2. Lesions in the
brainstem were heterogeneous. The reticular formation was
spared, but moderate (nucleus X and principal olivary nu-
cleus) to severe neuronal loss (hypoglossal, gracilis and cu-
neate nuclei) was observed in other brainstem regions in the
two cases. In Patient BG-2, neuronal loss was evidenced in
the ventro-lateral part of the zona compacta of the substan-
tia nigra but not in the pontine locus coeruleus (these struc-
tures were not available for Patient IT). The cerebellar cortex
was only atrophied in Patient IT with loss of Purkinje and
granule cells (Supplementary Fig. 2F). Anti-calbindin 28 kD
immunolabelling in Patient IT confirmed the rarefaction of
Purkinje cells (data not shown). Deep cerebellar nuclei were
not examined in the Italian patient but there was no abnor-
mality in the Belgian patient (data not shown). Finally, the
spinal cord was severely affected in the two cases.
Table 2 Neuropathological characteristics of SPG11 patients
Brain region Neuronal loss Astrocytic reactions
Patient IT Patient BG2 Patient IT Patient BG2
Frontal cortex Severe Severe Severe Moderate
Basal ganglia
Caudate Moderate Unaffected Moderate Unaffected
Putamen Moderate Unaffected Moderate Unaffected
Pallidum Unaffected Unaffected Unaffected Unaffected
Thalamus Severe Severe (mediodorsal nucleus) Severe Severe
Brainstem
Substantia nigra NE Moderate NE Moderate
Locus coeruleus NE Unaffected NE Unaffected
Pontine nuclei NE Unaffected NE Unaffected
Reticular formation Unaffected Unaffected Unaffected Unaffected
Nucleus cuneatus Severe Severe Moderate Moderate
Nucleus gracilis Severe Severe Moderate Moderate
Nucleus ambiguous Moderate Moderate Moderate Moderate
Nucl XII Severe Severe Moderate Moderate
Inferior olive Moderate Moderate Moderate Moderate
Cerebellum
Molecular layer Severe Unaffected Severe Unaffected
Purkinje cells Severe Unaffected Severe Unaffected
Granule cells Severe Unaffected Severe Unaffected
Dentate nucleus NE Unaffected Moderate Moderate
Spinal cord Severe Severe Severe Severe
NE = not examined.
ALS and SPG11 share pathological features BRAIN 2016: 139; 1723–1734 | 1727
 by guest on N
ovem
ber 16, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
Astrocytic reaction was evidenced by Holzer stain in
Patient BG-2 and by anti-GFAP immunohistochemistry in
two patients (Table 2). A mild fibrillary gliosis in the fron-
tal and temporal white matter and in the middle third of
the corpus callosum on a vertico-frontal section was
observed in Patient BG-2 while astrogliosis was more
severe in Patient IT, particularly in frontal cortex, thal-
amus, cerebellum and spinal cord, and was moderate in
basal ganglia and brainstem.
Neutral fat staining, performed in Patient BG-2 only, in
the absence of frozen tissues from Patient IT, was
unremarkable.
Cytological anomalies
Masson’s trichrome, Sudan black, Klu¨ver-Barrera (Fig. 1B)
or Nissl staining revealed abundant lipofuscin granules in
several parts of the brain and particularly in cerebral, pon-
tine and medullar neurons of both patients. In addition,
granular eosinophilic (Fig. 1A) and PAS+ (periodic acid
Schiff) structures different from classical lipofuscin granules
by size and polycyclic shape were found in the perikaryon
of remaining motor neurons of hypoglossal nucleus and the
anterior horns of the spinal cord. Anti-cathepsin D evi-
denced in both patients abundant granules, reminiscent of
lysosomes, with variable shape and size in neurons
from several brain regions, more precisely in subtentorial
areas (Supplementary Fig. 3A). Ubiquitin (Fig. 1C and
Supplementary Fig. 3C) and p62 (Fig. 1D and
Supplementary Fig. 3B) immunoreactive coarse granules
or beaded inclusions were also found in remaining peri-
karya of motor neurons in medulla oblongata and spinal
cord and in spinal ganglionic cells. The anti-ubiquitin and
anti-p62 antibodies did not reveal such structures in cortex,
basal ganglia or cerebellum, however none of these inclu-
sions were immunostained by anti-cystatin C (Fig. 1F) or
anti-TDP43 (Fig. 1E and Supplementary Fig. 3D).
The labelling against SMI32, in Patient IT, revealed ab-
normal accumulation of neurofilaments in motor neurons
of pontine nuclei and of spinal cord (data not shown). No
Figure 1 Neuronal rarefactions and presence of inclusions in the hypoglossal nucleus of Patient BG-2. Similar features were
observed in remaining neurons of the anterior horns of the spinal cord (data not shown). Large eosinophilic inclusions are observed in the
neuronal perikarya (arrows) after haematoxylin and eosin (A) or Klu¨ver-Barrera (B, blue) staining. Numerous inclusions (arrows) are immu-
noreactive for ubiquitin (C) or p62 (D). No labelling of the inclusions was evidenced with an anti-TDP-43 (E) or an anti-cystatin C antibody (F).
Scale bars = 50 mm.
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abnormal immunoreactivity against SMI31 neurofilaments
was detected in the two cases, except for a few sparse
spheroids and axon swellings in Patient IT.
The mutations of the SPG11 gene described in both pa-
tients are expected to lead to the loss-of-function of the
spatacsin protein by nonsense-mediated mRNA decay. In
agreement with this hypothesis, no immunolabelling with
antibodies directed against spatacsin developed and charac-
terized by us (Murmu et al., 2011), was obtained in brain
paraffin sections from the present cases (data not shown).
No Lewy bodies, neurofibrillary tangles, senile plaques
or intranuclear inclusions were observed either by histolo-
gical (haematoxylin and eosin, Masson’s trichrome
or Bodian silver impregnation) or immunohistochemical
staining (phosphorylated alpha-synuclein, hyperphosphory-
lated tau protein AT8 and amyloid-b 4G8 labelling).
In addition, no anti-FUS immunoreactivity was observed,
neither in spinal motor neurons nor in the remaining
neurons of the hypoglossal nucleus, in contrast to positive
anti-FUS inclusions observed in a control case with
Figure 2 Spinal ganglion of Patient BG-2. Haematoxylin and eosin staining highlighted large, mostly eosinophilic inclusions in the perikarya
of the ganglion cell neurons (A, arrows). Similar irregular inclusions were observed in the neuronal perikarya by Klu¨ver-Barrera staining (B,
arrows) or by an anti-ubiquitin (C) or and anti-p62 (D) antibody immunolabelling. The inclusions were not labelled by an anti-TDP-43 antibody (E,
arrows). Giant bodies or ‘retention bodies’ (arrows) were observed at electron microscopy of a ganglion cell (F, low magnification; G, high
magnification of a giant body). Classical lipofuscin granules were also present in these giant bodies (H). Scale bars: immunohistochemistry = 50
mm; electron microscopy = 1 mm.
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frontotemporal dementia carrying a FUS mutation (data
not shown).
Dorsal root ganglia exploration in
Patient BG-2
Ganglion neurons were also affected (such material was not
available for Patient IT). We observed, by haematoxylin
and eosin staining, eosinophilic inclusions associated with
refringent non-eosinophilic droplets (Fig. 2A). These inclu-
sions were also labelled by lipophilic Klu¨ver-Barrera stain-
ing (Fig. 2B). Their immunohistochemical characterization
showed that they were strongly ubiquitin-positive (Fig. 2C),
and some were also p62-labelled (Fig. 2D). As in the case
of motor neurons of cortex or spinal cord, they were not
stained by anti-TDP-43 (Fig. 2E).
Ultrastructural analysis of neuronal
inclusions
Electron microscopy of deparaffinized spinal ganglia neu-
rons of Patient BG-2 (Fig. 2F–H) showed many abnormal
electron dense storage materials: few giant bodies or ‘reten-
tion bodies’ (Fig. 2F arrows and Fig. 2G) (3–5 mm  4–8
mm) with closely clustered lipofuscin granules associated
with multiple lipid droplets (Fig. 2G) and a variety of het-
erogeneous aggregates (Fig. 2H).
In formalin-fixed anterior horns, motor neuronal peri-
karya showed large amounts of lipofuscin granules with
granular and osmiophilic amorphous aggregates but very
rare small-sized lipid droplets (Fig. 3A). Unusual electron-
lucent areas with no limiting membrane were closely inter-
mingled with lipofuscin in some neurons and they con-
tained variable amounts of cross- and longitudinal
sectioned fibrillary filaments (Fig. 3B arrows). The latter
had a densified and coarse tubular appearance with occa-
sional distortions at higher magnifications (data not
shown). A few deposits appeared partly wrapped in lipo-
fuscin granules. These abnormal deposits were not seen in
neurons in which lipid droplets appeared numerous and
larger, such as usually observed. Finally, similar features
were not seen in control spinal cord neurons containing
numerous lipofuscin granules and in a proven case of
ALS due to a C9orf72 abnormal repeat expansion (data
not shown).
Additionally, no intranuclear inclusions were seen in neu-
rons and glial cells of spinal anterior horn and ganglia
specimens.
Discussion
We report here the first neuropathological description of
two patients with HSP from genetically proven SPG11
families. The two cases share similar lesions, including cor-
tical atrophy, white matter involvement with myelin pallor
and severe astrogliosis. They also share a demyelination of
the pyramidal pathways and loss of motor neurons in me-
dulla oblongata and anterior horns of spinal cord. The
thalamus of the two cases was also affected, especially
the mediodorsal nucleus of Patient BG-2.
In contrast, there were some differences in severity of the
lesions between the two cases in the basal ganglia and cere-
bellum (Table 2). The cerebellar cortex of Patient IT was
severely affected after 22 years of disease duration (onset at
age 10 years), while it was spared in Patient BG-2 after 36
years of disease duration (onset also at age 10 years) in
spite of a cerebellar syndrome in both patients. Patient
BG-2 showed moderate gliosis of dentate nucleus that
could however account for the observed cerebellar ataxia.
Why the involvement of specific neuronal populations and
the severity of the lesions varied between the two cases
Figure 3 Electron micrographs of a motor neuron of the
anterior horn of the lumbosacral spinal cord. (A) Presence of
electron-lucent zones (arrows) intermingled with lipofuscin. The
area indicated by the horizontal arrow in (A) is shown at a higher
magnification in (B, arrows).
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remain an unresolved question. Other genetic or environ-
mental factors might have played a role.
Other clinicopathological studies of HSP cases have been
reported, but without genetic investigations. More particu-
larly, two reported cases share similar clinical and neuro-
pathological characteristics with ours (Wakabayashi et al.,
2001; Kuru et al., 2005). After 37 years of disease dur-
ation, the first patient had a slowly progressive spastic
tetraplegia with mental deterioration and severe amyot-
rophy. Marked cerebral atrophy with thin corpus callosum
was shown by brain MRI. The second patient had spastic
paraplegia, mental retardation and amyotrophy with sen-
sory disturbances after a disease duration of 26 years.
Interestingly, while the cerebellum was atrophied in the
first case, it was normal in the second case, which mimics
the heterogeneity also found in our two SPG11 patients. A
severe thinning of the corpus callosum was present in both
autopsies. In these two published cases, the remaining neu-
rons also presented abundant eosinophilic and lipofuscin
granules, which were partially identified as anti-ubiquitin
positive in one case (Wakabayashi et al., 2001), but were
not fully characterized. As between our two cases, some
differences between the two Japanese cases themselves
could result from the circumstances of death or different
time in post-mortem examination. In addition, we cannot
exclude different genetic conditions in the two Japanese
cases as the SPG11 gene was not tested.
Overlapping findings between our
SPG11 cases and ALS
Our SPG11 patients partially shared various clinical and
neuropathological features of ALS.
The neuropathological features, especially observed in
subtentorial areas, namely medulla oblongata and spinal
cord, including the dorsal columns, are reminiscent of find-
ings already observed in ALS, thus emphasizing a putative
physiological link between SPG11 mutations and some
forms of ALS. In agreement with this observation, SPG11
mutations were recently reported in autosomal recessive
juvenile ALS with unusual long disease durations
(Orlacchio et al., 2010; Daoud et al., 2012). The brainstem
and spinal cord autopsy of one of these juvenile ALS pa-
tients mutated in SPG11 showed minor lesions after 33
years of disease duration (Orlacchio et al., 2010).
Neuronal loss and astrogliosis were limited to glossopha-
ryngeal and hypoglossal nuclei and to the anterior horn of
the spinal cord, and a myelin pallor was reported in the
anterolateral columns. The remaining motor neurons of the
spinal cord showed central chromatolysis, pigmentary de-
generation and hyaline inclusions that were not character-
ized using immunohistochemistry markers. Neither Bunina
bodies nor skein-like inclusions were observed.
In our SPG11 cases, Bunina bodies were also not evi-
denced by the anti-cystatin-C antibody. Peculiar observa-
tions were, however, found in our patients; the
supratentorial structures—namely frontotemporal cortex,
basal ganglia and the thalamic mediodorsalis nucleus—
showed neuronal degeneration without the immunohisto-
chemical landmark of ALS pathology as we did not observe
ubiquitin, p62, or TDP-43 immunoreactivity either in basal
ganglia or in the neocortex. In medulla oblongata and
spinal cord, however, ubiquitin and p62-positive granules
were found. Indeed, the accumulation and/or aggregation
of neurofilaments in motor neuron perikarya and axons
(axonal spheroids) together with the abnormal topographic
location of neurofilaments in the cell body are classical
features associated with familial and sporadic ALS
(Delisle and Carpenter, 1984; Xiao et al., 2006).
Moreover, a clinical overlap between complicated HSP
and ALS was overt in Patient BG-2. In the end stage of
her disease, there was a severe bulbar palsy in addition to
severe cerebellar dysarthria. There were severe feeding
problems and a percutaneous endoscopic gastrostomy
tube was needed. There was an evolution to a proximal
and distal amyotrophy and a spastic quadriparesis. All
this suggests a clinical evolution toward a complicated
form of HSP with involvement of the lower motor
neuron and a more severe ALS-like phenotype. However,
fasciculations were seen at that time and no ENMG was
performed at that stage, which could have supported the
diagnosis of ALS.
SPG11 pathology includes abnormal
aggregation and lipid storage
Lipofuscin-positive granules were abnormally abundant in
supratentorial neurons of our SPG11 patients and in the
anterior horn associated with granular osmiophilic
amorphous aggregates. Interestingly, granular intracyto-
plasmic eosinophilic/PAS+ structures were exclusively
found in motor neurons in spinal cord and hypoglossal
nucleus. All these deposits were restricted to neurons and
were labelled with anti-cathepsin-D as lysosomal-like struc-
tures in supratentorial areas, and by anti-ubiquitin and
anti-p62 in spinal cord neurons and ganglion cells.
Although we showed, by electron microscopy, unusual fi-
brillary filaments intermingled with lipofuscin deposits, no
relationship could be established with the immunostained
inclusions in the absence of immuno-electron microscopy.
The abundance of pigment granules in neurons seems to
represent a cytopathological hallmark of SPG11. Recent
studies showed that SPG11 and SPG15 proteins interact
with the late endosomal/lysosomal adaptor protein complex
AP-5 (Hirst et al., 2013) and their involvement in this path-
way is consistent with the abnormal lysosomal storage evi-
denced in fibroblasts from SPG11, SPG15 and SPG48
patients (Renvoise´ et al., 20014; Hirst et al., 2015). Very
recently, an Spg11 knockout mouse model was reported to
recapitulate the major clinical features of the human disease
(Varga et al., 2015). Briefly, the Spg11 knockout mice de-
veloped symptoms reminiscent to spastic paraplegia with
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progressive loss of cortical motor neurons and Purkinje cells,
as we observed in the human pathology (present study).
Degenerating neurons accumulated autofluorescent material,
which was dark and osmiophilic at the electron microscopy
level, consistent with the accumulations observed in our
human brain samples. The neuronal inclusions in the knock-
out mouse model were partially immunostained with anti-p62
and with the anti-lysosomal membrane protein LAMP1, sup-
porting the observation of lysosome/autophagy defects. In
addition, morphological analysis of neurons from Spg15
knockout mice also showed accumulation of large intraneur-
onal deposits of membrane-surrounded material, which co-
stained with the lysosomal marker LAMP1 (Khundadze et
al., 2013). Although differences exist between human and
mouse brains, the aformentioned observations indicate that
the invalidation of Spg11 in the mouse mimics the pathology
we observed in SPG11 patients and this is relevant for future
studies aimed at identifying potential therapeutic avenues.
Taken together, these results argue in favour of a lyso-
somal impairment in SPG11 and SPG15. The abnormal
deposits observed in our SPG11 cases are also reminiscent
of other pathological hallmarks of motor neuron diseases
associated with mutations in other genes. Motor neuron
inclusions (e.g. granular lesions, ubiquitin, TDP-43, and/
or p62 positive structures) may represent a pivotal feature
of these diseases. TDP-43 accumulation is observed in pa-
tients with mutations in GRN (progranulin), C9orf72,
DCTN1 (dynactin), OPTN (optineurin), VCP (valosin-con-
taining protein), ANG (angiogenin) (Da Cruz and
Cleveland, 2011), but not in our SPG11 cases. On the
other hand, TDP-43 proteinopathy with widespread
spinal cord and cerebral skein-like and round neuronal
cytoplasmic inclusions has recently been observed in pa-
tients with NIPA1 (SPG6) mutation associated with ALS
clinical features (Martinez-Lage et al., 2012). Regarding
p62 deposits, the evidence of their involvement in neurode-
generative diseases is growing (Zatloukal et al., 2002). The
p62 protein, after mono- or poly-ubiquitination, is asso-
ciated with autophagy (Rubinsztein et al., 2012). The cyto-
logical association between LC3 and p62 markers in
neuronal inclusions may indicate autophagic degradation
of misfolded proteins. Inhibition of autophagy and increas-
ing levels of p62 are generally correlated and p62 itself is
degraded by autophagy (Zatloukal et al., 2002; Sasaki,
2011; Martinez-Lage et al., 2012). In Lewy body disease,
it was shown that p62 deposition precedes ubiquitination
(Kuusisto et al., 2003) but p62, ubiquitin and TDP-43 de-
position kinetics remains unknown; further biochemical
studies and cellular and animal model analyses are
needed to elucidate these kinetics. In our SPG11 patients,
the deposition of p62 and ubiquitination were only
observed in subtentorial neurons and dorsal root ganglia.
The differences in composition of the aggregates according
to neuronal populations remain unanswered and we can
hypothesize that the immunohistochemical discrepancy be-
tween p62 and TDP-43 deposits observed in the present
SPG11 cases and as reported by others (King et al.,
2011) could be explained by two different hypotheses.
Different kinetics of deposition of these proteins may vary
according to the subpopulations of neurons. Alternatively,
SPG11 could represent a subtype of motor neuron path-
ology in which TDP-43 does not aggregate, as it has been
observed in the human pathology and in a mouse model of
ALS/frontotemporal lobar degeneration due to multivesicu-
lar body protein (CHMP2B) gene mutation (Ghazi-Noori
et al., 2012).
In conclusion, this study, performed in two distinct sib-
ships, is the first report of brain and spinal cord autopsy in
complex forms of hereditary spastic paraplegia with SPG11
mutations. We demonstrate the neuropathological link be-
tween HSP and ALS in terms of neurodegeneration top-
ology and show for the first time the existence of
abnormal accumulations in neurons of SPG11, a disorder
that can then be added to the growing list of diseases asso-
ciated with aggregates. Further studies, using animal and
cellular models may determine if the aggregation of pro-
teins and lysosomal abnormalities with abnormal lipidic
deposits may precede axonal dying back, which was pro-
posed as a pathological mechanism associated with HSP
(Behan and Maia 1974; Deluca et al., 2004).
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